Efficacy of rapamycin against glioblastoma cancer stem cells
作者： M. Mendiburu-Eliçabe , J. Gil-Ranedo , M. Izquierdo
DOI: 10.1007/S12094-013-1109-Y
关键词: RPTOR 、 Immunology 、 Cancer research 、 Cancer stem cell 、 Protein kinase B 、 mTORC1 、 Phosphatidylinositol 、 Population 、 PI3K/AKT/mTOR pathway 、 Biology 、 Kinase
摘要: Purpose The cancer stem cell (CSC) hypothesis suggests a hierarchical organization of cells within the tumor, in which only subpopulation stem-like is responsible for rise and progression tumor. Glioblastomas (GBM), lethal brain may contain variable proportion active CSCs. On other hand, phosphatidylinositol 3-kinase (PI3 K)/Akt/mammalian target rapamycin (mTOR) pathway highly up to 70 % GBM. The kinase mTOR key component PI3K that mediates regulation growth survival signaling. However, clinical trials with rapamycin, an effective inhibitor mTOR, have not been created expectations plausible explanation missing. In this work, we analyze effect on GBM-CSC population.
springer.com
unirioja.es
sci-hub.se 参考文章(31)
D. Akhavan, T. F. Cloughesy, P. S. Mischel, mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro-oncology. ,vol. 12, pp. 882- 889 ,(2010) , 10.1093/NEUONC/NOQ052
Susan M. Chang, , Patrick Wen, Timothy Cloughesy, Harry Greenberg, David Schiff, Charles Conrad, Karen Fink, H. Ian Robins, Lisa De Angelis, Jeffrey Raizer, Kenneth Hess, Ken Aldape, Kathleen R. Lamborn, John Kuhn, Janet Dancey, Michael D. Prados, Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investigational New Drugs. ,vol. 23, pp. 357- 361 ,(2005) , 10.1007/S10637-005-1444-0
A Iwamaru, Y Kondo, E Iwado, H Aoki, K Fujiwara, T Yokoyama, G B Mills, S Kondo, Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene. ,vol. 26, pp. 1840- 1851 ,(2007) , 10.1038/SJ.ONC.1209992
Igor Vivanco, Charles L. Sawyers, The phosphatidylinositol 3-Kinase–AKT pathway in human cancer Nature Reviews Cancer. ,vol. 2, pp. 489- 501 ,(2002) , 10.1038/NRC839
Peter J. Houghton, Everolimus: Fig. 1. Clinical Cancer Research. ,vol. 16, pp. 1368- 1372 ,(2010) , 10.1158/1078-0432.CCR-09-1314
Groothuis, The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-oncology. ,vol. 2, pp. 45- 59 ,(2000) , 10.1215/S1522851799000307
Christine E. Eyler, Wen-Chi Foo, Katherine M. LaFiura, Roger E. McLendon, Anita B. Hjelmeland, Jeremy N. Rich, Brain Cancer Stem Cells Display Preferential Sensitivity to Akt Inhibition Stem Cells. ,vol. 26, pp. 3027- 3036 ,(2008) , 10.1634/STEMCELLS.2007-1073
Alejo Efeyan, David M Sabatini, mTOR and cancer: many loops in one pathway Current Opinion in Cell Biology. ,vol. 22, pp. 169- 176 ,(2010) , 10.1016/J.CEB.2009.10.007
Anne-Marie Bleau, Jason T. Huse, Eric C. Holland, The ABCG2 resistance network of glioblastoma. Cell Cycle. ,vol. 8, pp. 2936- 2944 ,(2009) , 10.4161/CC.8.18.9504
Oliver Dreesen, Ali H. Brivanlou, Signaling Pathways in Cancer and Embryonic Stem Cells Stem Cell Reviews and Reports. ,vol. 3, pp. 7- 17 ,(2007) , 10.1007/S12015-007-0004-8